Immunogenicity, Safety, and Reactogenicity of SARS-CoV-2 Vaccine mRNA-1273 in Heterologous Prime-Boost with Protein-Based MVC-COV1901: A Randomized, Double-Blind Study

28 November 2022|

During the COVID pandemic, the most broadly administered vaccines were of the mRNA platform. With recent health concerns tied to that platform, boosting with other vaccine types became of interest. In this study, participants were injected with the MVC vaccine as a booster in people previously vaccinated with Moderna. All participants had a robust immune response, both in antibodies and cellular immunity levels, that provided protection against Omicron.


An Evaluation of the Safety and Immunogenicity of MVC-COV1901: Results of an interim analysis of a phase III, parallel group, randomized, double-blind, active-controlled Immunobridging study in Paraguay

18 November 2022|Vaccine

In this phase III trial, a collaboration was made with Paraguayan health authorities to compare the MVC vaccine's immunogenicity against AstraZeneca's in different populations. Here, MVC presented superiority to AstraZeneca in generating neutralizing antibodies, all while having less adverse effects.


Safety and immunogenicity of a heterologous booster of protein subunit vaccine MVC-COV1901 after two doses of adenoviral vector vaccine AZD1222

11 October 2022|Vaccines (MDPI)

As months passed and newer variants emerged, the world needed booster shots to remain appropriately protected. In this phase II clinical study, the MVC vaccine was tested as a booster on people previously vaccinated with AstraZeneca. Anti-spike antibodies increased 14-fold and neutralization against Omicron variant was concurrenlty achieved.


A randomized controlled trial of heterologous ChAdOx1 nCoV-19 and recombinant subunit vaccine MVC-COV1901 against COVID-19

7 October 2022|Nature Communications

Third party.


Neutralization of SARS-CoV-2 Omicron BA.4/BA.5 subvariant by a booster dose of bivalent adjuvanted subunit vaccine containing Omicron BA.4/BA.5 and BA.1 subvariants

7 October 2022|bioRxiv

The strongest version of Omicron so far has been the BA.4 and BA.5 subvariant. In order to test better ways to protect against these, this pre-clinical study injected mice with a new vaccine formulation containing Omicron variants BA.1 or BA.4/5. Boosting with the bivalent Omicron formulations gave the highest neutralizing antibody generation.


Neutralization of SARS‑CoV‑2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV‑19, mRNA‑1273, MVC‑COV1901 and booster mRNA‑1273 vaccination

15 September 2022|Infection (Springer)

Third party.


A Phase I, Prospective, Randomized, Open-labeled Study to Evaluate the Safety, Tolerability, and Immunogenicity of Booster Dose with MVC-COV1901 or MVC-COV1901(Beta) SARS-CoV-2 Vaccine in Adults

30 August 2022|MedRxiv

Following the success of the Beta variant vaccine pre-clinical hamster studies, this phase I trial tested two doses of Beta MVC vaccine as a booster on participants previously vaccinated with the original MVC vaccine. Adverse reactions were as mild as with the original, and the booster managed to significantly improve neutralizing antibodies against both Beta and Omicron variants.


Safety and Immunogenicity of MVC-COV1901 Vaccine in Older Adults: Phase 2 Randomized Dose-Comparison Trial

29 August 2022|International Journal of Infectious Diseases

The elder population remain in greatest danger of COVID-19 infection and mortality. In this phase II analysis, different doses of MVC vaccine were analyzed to determine the best choice for elderly with comorbidities. 


Protection of Hamsters Challenged with SARS-CoV-2 after Two Doses of MVC-COV1901 Vaccine Followed by a Single Intranasal Booster with Nanoemulsion Adjuvanted S-2P Vaccine

5 July 2022|Scientific Reports

The Omicron variant was extremely effective at avoiding immune defenses, and new strategies had to be devised to stop its spread. Nasal immunity is the first line of protection against viruses, and in this pre-clinical study, the MVC vaccine was tested as an intranasal booster. Hamsters not only developed robust immunity against COVID-19, but also increased their viral clearance in both the upper and lower respiratory tracts.


Durability and Immunogenicity of Neutralizing Antibodies Response Against Omicron Variants After Three Doses of Subunit SARS-CoV-2 Vaccine MVC-COV1901: An Extension to an Open-Label, Dose-Escalation Phase 1 Study

17 May 2022|Infection Diseases and Therapy

Continuing the booster studies, this phase I clinical trial was performed to test the MVC vaccine as a booster on people already vaccinated with an MVC primary series. Not only were antibody levels brought up to 28 times higher than before the booster, but these lasted up to 6 months after.

We use cookies to improve your user experience and for web traffic statistics purposes. By continuing to use this website, you agree to our use of cookies. Our Privacy & Cookie Policy contains more information on such use and explains how to disable cookies.